Premium
Adherence to infliximab therapy in inflammatory bowel disease patients in a real‐life setting
Author(s) -
Martelli Laura,
Lopez Anthony,
Strobel Sophie,
Danese Silvio,
Roblin Xavier,
Baumann Cédric,
PeyrinBiroulet Laurent
Publication year - 2017
Publication title -
journal of digestive diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.684
H-Index - 51
eISSN - 1751-2980
pISSN - 1751-2972
DOI - 10.1111/1751-2980.12539
Subject(s) - medicine , infliximab , inflammatory bowel disease , ulcerative colitis , disease , referral , odds ratio , observational study , family medicine
OBJECTIVE To assess adherence to infliximab (IFX) therapy in inflammatory bowel disease patients, to investigate reasons for non‐adherence and to identify predictors for non‐adherence. METHODS This observational study was conducted in two French referral university hospitals between 1 September and 31 October, 2011. Patients were systematically asked if they had already delayed or missed an IFX perfusion since the beginning of the treatment and about the reasons for their non‐adherence. RESULTS Of the 162 included patients (121 Crohn's disease [CD], 41 ulcerative colitis), 87 (53.7%) reported a delay of at least one IFX injection and 14 (8.6%) missed at least one IFX perfusion since the beginning of the treatment. The overall non‐adherence rate was 54.3%. Pooling all misses, the main reasons for non‐adherence were pregnancy (33.3%), intentional non‐adherence (20%) and forgetfulness (13.3%). Pooling all delays, the main reasons for non‐adherence were professional constraints (46.9%), infections (17.3%) and travels (14.3%). Perineal disease was associated with IFX delays ( P = 0.0007, odds ratio 4.0), whereas active CD/UC was associated with IFX misses ( P = 0.0258, OR = 5.4). CONCLUSIONS The overall non‐adherence rate for IFX use was 54.3%. Professional constraints and intentional non‐adherence were the leading causes of non‐adherence. Perineal disease and active CD were negatively related to adherence.